Last reviewed · How we verify
Influenza vaccine GSK2321138A
Influenza vaccine GSK2321138A is a vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Influenza prevention in adults.
GSK2321138A is a recombinant influenza vaccine designed to stimulate immune responses against influenza virus antigens.
GSK2321138A is a recombinant influenza vaccine designed to stimulate immune responses against influenza virus antigens. Used for Influenza prevention in adults.
At a glance
| Generic name | Influenza vaccine GSK2321138A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As an investigational influenza vaccine, GSK2321138A likely contains viral antigens or recombinant proteins that prime both humoral and cellular immune responses to protect against influenza infection. The specific formulation and adjuvant strategy are proprietary to GlaxoSmithKline, but the vaccine aims to induce protective antibodies and T-cell responses against circulating influenza strains.
Approved indications
- Influenza prevention in adults
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children (PHASE2)
- An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children (PHASE3)
- Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A) (PHASE3)
- Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children (PHASE2)
- Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children (PHASE3)
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older (PHASE3)
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345 (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenza vaccine GSK2321138A CI brief — competitive landscape report
- Influenza vaccine GSK2321138A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Influenza vaccine GSK2321138A
What is Influenza vaccine GSK2321138A?
How does Influenza vaccine GSK2321138A work?
What is Influenza vaccine GSK2321138A used for?
Who makes Influenza vaccine GSK2321138A?
What drug class is Influenza vaccine GSK2321138A in?
What development phase is Influenza vaccine GSK2321138A in?
What are the side effects of Influenza vaccine GSK2321138A?
Related
- Drug class: All vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Influenza prevention in adults
- Compare: Influenza vaccine GSK2321138A vs similar drugs
- Pricing: Influenza vaccine GSK2321138A cost, discount & access